News
Vantia Therapeutics appoints new CEO
9 June 2010
Vantia Therapeutics today announced that it has appointed Andrew Crockett to the position of Chief Executive Officer (CEO). more»
VA111913 structure revealed
26 March 2010
Vantia Therapeutics reveals structure of its novel small molecule treatment for dysmenorrhoea, VA111913, at the ACS National Meeting. more»
Vantia Therapeutics Pipeline
Vantia Therapeutics' pipeline draws on the Company's world-recognised expertise in small molecule drug development. Its drug discovery engine is based on the Ferring Research Ltd small molecule R&D unit, which was spun out from Ferring Pharmaceuticals in 2008. Focussed on first-in-class therapies for indications that are under-served by current products, Vantia Therapeutics' R&D group has over 20 years' experience in the development of small molecule modulators targeting hormones and proteases.
The Company owns an extensive drug candidate library, which is driving its clinical and preclinical portfolio, and intellectual property comprising 20 patent families and 21 granted patents.
The current status of Vantia Therapeutics' pipeline is shown below - click on a compound name, or click the links under the "Pipeline" menu on the left, for more information.
| Platform | Compound | Indication(s) | MOA | Market Potential | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Year of NDA Target |
|---|---|---|---|---|---|---|---|---|---|
| GPCR | VA106483 | Nocturia | V2 Agonist | $1bn |  |
|
 |
2012 | |
| GPCR | VA111913 | Dysmenorrhoea | V1a Antagonist | $1-3bn | |
|
|
2013 | |
| Tissue Kallikrein | VA118020 | Severe Asthma | KLK1 Inhibitor | $3-7bn | |
2014 | |||
| Tissue Kallikrein | multiple | Inflammatory | KLK1 Inhibitor | TBA | |
TBA | |||
| Plasma Kallikrein | multiple | HAE/Diabetes | PKal Inhibitor | $1-2bn | |
2016 | |||
| FAP Inhibitor | VA999260 | Oncology/ Fibrosis | FAP Inhibitor | TBA | |
2016 | |||
| FAP Inhibitor | multiple | Oncology/ Fibrosis | FAP Inhibitor | TBA | |
TBA |
